CAMP4 Therapeutics (NASDAQ:CAMP) Coverage Initiated by Analysts at Raymond James Financial

Raymond James Financial initiated coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a report released on Friday, Marketbeat reports. The brokerage set a “strong-buy” rating and a $10.00 price target on the Wireless communications provider’s stock. Raymond James Financial‘s target price points to a potential upside of 194.99% from the company’s current price.

Several other equities research analysts also recently weighed in on CAMP. UBS Group set a $15.00 price objective on CAMP4 Therapeutics in a report on Friday, August 14th. Zacks Research upgraded shares of CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 17th. Needham & Company LLC began coverage on shares of CAMP4 Therapeutics in a report on Thursday, October 15th. They issued a “buy” rating and a $8.00 target price on the stock. Wall Street Zen downgraded shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Finally, Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, CAMP4 Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $10.44.

CAMP4 Therapeutics Price Performance

Shares of NASDAQ CAMP opened at $3.39 on Friday. CAMP4 Therapeutics has a 52-week low of $2.90 and a 52-week high of $7.75. The business has a 50-day moving average price of $4.04 and a 200 day moving average price of $4.14.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings results on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.34). The firm had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%. As a group, sell-side analysts expect that CAMP4 Therapeutics will post -0.66 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Kelly Gold bought 10,000 shares of the stock in a transaction on Monday, August 31st. The shares were bought at an average cost of $3.96 per share, for a total transaction of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at $39,600. This trade represents a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Richard Young bought 16,378 shares of the stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the purchase, the director directly owned 186,388 shares in the company, valued at approximately $307,540.20. The trade was a 9.63% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders purchased 46,031 shares of company stock valued at $99,051 and sold 593,613 shares valued at $2,504,037. 21.69% of the stock is owned by insiders.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CAMP. Bank of America Corp DE acquired a new position in CAMP4 Therapeutics in the 2nd quarter valued at $78,000. Deutsche Bank AG purchased a new position in CAMP4 Therapeutics during the 2nd quarter worth $138,000. Bank of New York Mellon Corp acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth $365,000. SummitTX Capital L.P. acquired a new stake in shares of CAMP4 Therapeutics in the 1st quarter worth $1,497,000. Finally, BlackRock Inc. acquired a new stake in shares of CAMP4 Therapeutics in the 2nd quarter worth $7,185,000.

CAMP4 Therapeutics Company Profile

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.